Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system.

Limbert, M.; Bartlett, Richard; Dickneite, Gerhard; Klesel, N; Schorlemmer, H. U.; Seibert, Gerhard; Winkler, Irvin; Schrinner, E

doi:10.7164/antibiotics.37.1719

Cited by 34 publications

(15 citation statements)

References 34 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vivo superiority of cefodizime was also particularly marked in immunocompromised animal models [31,32]. Limbert et al [14] demonstrated both enhanced chemilumi nescence production and phagocytosis in peritoneal mac rophages in Balb/c mice treated with cefodizime. An in creased response to B-cell mitogens in lymphocytes and longer survival times in Candida albicans-infected mice were also observed.…”

Section: Discussionmentioning

confidence: 99%

“…Antibiotics are current ly believed to have a neutral effect on phagocytic capacity although it has been suggested that some exert a depressant effect on phagocyte function [13] which would be particu larly indesirable in immunodeficient patients. Animal studies on a new aminothiazolyl cephalosporin, cefodizime, suggested that this drug has biological-response-mod ifying properties [14]. Investigations in healthy volunteers [15] and preliminary clinical studies in urémies [16] sup ported this assumption.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Vanholder

Dagrosa²,

Landschoot

et al. 1993

Nephron

View full text Add to dashboard Cite

Twenty-three stabilized chronic uremic patients with no active or recent infection were treated for 10 days with either cefodizime (5 × 2 g intravenously, n = 10) or cotrimoxazole (960 mg orally b.i.d., n = 8) in order to evaluate the effects on the depressed polymorphonuclear metabolic response to phagocytic challenge; a separate group of 5 patients received placebo. Ex vivo evaluation in whole blood of energy delivery to the phagocytosis-associated respiratory burst activity in response to latex and zymosan challenge was determined by measuring hexose-monophosphate shunt NAD(P)H-oxidase-related glycolytic activity. Cefodizime induced a statistically significant increase in the baseline-depressed glycolytic response for both latex and zymosan challenge, in contrast to cotrimoxazole and placebo. Depressed phagocytosis-related metabolic function in hemodialyzed patients was stimulated by cefodizime in recommended therapeutic doses but not by cotrimoxazole, the effect persisting for at least 2 weeks after the end of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Vanholder

Dagrosa²,

Landschoot

et al. 1993

Nephron

View full text Add to dashboard Cite

show abstract

“…In 1984 the first report on the innovative, nonantibacterial properties of cefodizime, a new 2-amino-5-thiazolyl cephalosporin, appeared in the Journal of Antibiotics (225). This paper summarized in vitro and in vivo data obtained by Hoescht Abteilung Geselschafft in Frankfurt, which suggested that cefodizime (HR-221) displayed original properties unrelated to its antibacterial efficacy.…”

Section: Immunostimulation or Restoration?mentioning

confidence: 99%

Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or "Immuno-Fairy Tales"?

Labro¹

2000

Clinical Microbiology Reviews

151

View full text Add to dashboard Cite

“…The immunomodulating activity of several antimicrobial agents has been investigated in the past (19,21,25,27). Unfortunately, most of these studies have focused on in vitro effects (10,14,15,37).…”

mentioning

confidence: 99%

“…In addition, the in vitro effects of this drug include an alteration of bacterial virulence factors (23). In vivo models of experimental infections show that the prophylactic administration of cefodizime increases the survival of some strains of mice after challenge with Toxoplasma gondii or Candida albicans (19,25); its curative effect in infections due to members of the family Enterobacteriaceae is better than what might have been expected from its in vitro MIC determinations relative to that of other expanded-spectrum cephalosporins (1,22). This effect is even more marked in immunocompromised animals (19,25).…”

mentioning

confidence: 99%

Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections

Wenisch

Parschalk

Hasenhündl

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Thirty patients with severe bacterial infections were treated with 50 mg of cefodizime per kg of body weight once daily or 50 mg of ceftriaxone per kg once daily for 10 ؎ 3 days. The effect of cefodizime and ceftriaxone on the phagocytic capacity and generation of reactive oxygen intermediates after phagocytosis by granulocytes was assessed prior to, during, and after therapy. Flow cytometry was used to study phagocytic capacity by measuring the uptake of fluorescein-labeled bacteria. The generation of reactive oxygen intermediates after phagocytosis was estimated by the quantification of the intracellular conversion of dihydrorhodamine 123 to rhodamine 123. Prior to therapy, patients in both groups exhibited a decreased capacity to phagocytize Escherichia coli and subsequently to generate reactive oxygen intermediates. Granulocyte function increased after the initiation of therapy and normalized within 7 days for the ceftriaxone-treated patients and within 3 days for the cefodizime group (P < 0.05). In the cefodizime group, an enhancement of phagocytic capacity was observed 14 days after the initiation of therapy (P < 0.05). Prior to therapy, phagocytic capacity was significantly correlated with the generation of reactive oxygen products (r ‫؍‬ 0.674 and P < 0.005).

show abstract

Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system.

Cited by 34 publications

References 34 publications

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or "Immuno-Fairy Tales"?

Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections

Contact Info

Product

Resources

About